DT2219, a bispecific ligand-directed toxin targeting both CD22 and CD19, is conjugated to the catalytic domain of diphtheria toxin and is used for treating refractory or relapsed B-lineage leukemia or lymphoma.386. This evidence concerns the gene CD19 and lymphoma.